Physician

Christopher Andrew Yasenchak, M.D.

According to 2025 Medicare claims, Christopher Yasenchak, M.D. (NPI: 1508830670) practices hematology/oncology in the Eugene-Springfield, OR market, with the plurality of this provider's patient population coming from Lane, OR. This provider's primary affiliated billing organization is ONCOLOGY ASSOCIATES OF OREGON P C (NPI: 1013989854; TIN: 930746296) and primary practice location at 97401-6036. Yasenchak is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Yasenchak's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 610 traditional Medicare patients, billed 138,450 HCPCS/CPT codes, and received $2,621,312 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,454 prescription claims across 221 beneficiaries totaling $4,677,629 in drug costs, led by Brukinsa (Zanubrutinib). 2018 DME data shows 14 claims. Open Payments data shows 72 records totaling $94,616. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,355,533 and ending at $2,621,312. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,072,505 to $4,677,629. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	343	80,818	$1,355,533
2016	412	133,512	$1,883,023
2017	457	116,505	$1,838,192
2018	438	85,504	$1,424,456
2019	469	105,214	$1,925,433
2020	465	100,905	$1,747,865
2021	460	108,809	$1,862,535
2022	420	112,205	$1,938,118
2023	434	89,653	$1,489,696
2024	610	138,450	$2,621,312

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	162	1,045	$1,072,505
2016	200	1,398	$1,972,163
2017	192	1,502	$2,701,887
2018	187	1,426	$3,819,110
2019	190	1,548	$3,450,024
2020	207	1,727	$5,033,717
2021	216	1,683	$5,573,858
2022	199	1,425	$4,459,412
2023	198	1,360	$4,462,549
2024	221	1,454	$4,677,629

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	41	$4,457
2016	N/R	13	$772
2017	N/R	25	$1,969
2018	N/R	14	$4,252
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	167	332	$99
80053	Blood test, comprehensive group of blood chemicals	323	865	$10
36415	Insertion of needle into vein for collection of blood sample	347	956	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	320	893	$8
83615	Lactate dehydrogenase (enzyme) level	165	393	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	125	3,750	$1,599,403
Lenalidomide	Lenalidomide	52	1,407	$673,084
Jakafi	Ruxolitinib Phosphate	48	1,413	$435,414
Ojjaara	Momelotinib Dihydrochloride	13	390	$360,634
Pomalyst	Pomalidomide	11	301	$208,101

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$10,342	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	66	$84,275	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christopher Andrew Yasenchak, M.D.?

Tedicare shows public-source Medicare data for Christopher Andrew Yasenchak, M.D. (NPI 1508830670), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christopher Andrew Yasenchak, M.D. have ACO affiliation data?

Christopher Andrew Yasenchak, M.D. is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Christopher Andrew Yasenchak, M.D.?

Christopher Andrew Yasenchak, M.D. is linked to ONCOLOGY ASSOCIATES OF OREGON P C (billing NPI 1013989854) in the available physician profile data.

Does Christopher Andrew Yasenchak, M.D. have Open Payments data?

Christopher Andrew Yasenchak, M.D. has 72 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.